NasdaqGM:VNDABiotechs
Vanda Pharmaceuticals (VNDA) Q4 Loss Surge Challenges Bullish Valuation Narratives
Vanda Pharmaceuticals (VNDA) has just posted its FY 2025 results with fourth quarter revenue of US$57.2 million and a quarterly loss per share of US$2.39, while trailing 12 month revenue came in at US$216.1 million alongside a loss per share of US$3.74. Over recent quarters the company has seen revenue move from US$47.7 million in Q3 2024 to US$57.2 million in Q4 2025, as quarterly EPS moved from a loss of US$0.09 to a loss of US$2.39. This has left investors focused squarely on how quickly...